• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PASG

    Passage Bio Inc.

    Subscribe to $PASG
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: passagebio.com

    Peers

    $ALEC
    $BXRX
    $GBIO
    $GOSS
    $GRTS
    $SIOX
    $TSHA
    $TIL
    $IMPL
    $PALI
    $GRPH

    Recent Analyst Ratings for Passage Bio Inc.

    DatePrice TargetRatingAnalyst
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    9/3/2024$7.00Buy
    Rodman & Renshaw
    3/8/2022Overweight → Neutral
    JP Morgan
    3/4/2022$29.00 → $24.00Outperform
    Raymond James
    1/19/2022$29.00 → $6.00Buy → Neutral
    Goldman
    7/1/2021$29.00Outperform
    Raymond James
    See more ratings

    Passage Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc sold $197,239 worth of shares (583,657 units at $0.34) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      6/26/25 5:10:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kapadia Sandip

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 9:41:02 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gowen Maxine

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:31:13 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Countouriotis Athena

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:30:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Porter Derrell

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:29:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Islam Saqib

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:28:38 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sondhi Dolan

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:27:46 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kassberg Thomas Richard

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:26:39 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $78,731 worth of shares (235,572 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/24/25 5:38:49 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $49,704 worth of shares (149,054 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/17/25 6:10:47 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care